Show notes
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — Madrigal wins first FDA nod for NASH
The ugly — BIO backs BIOSECURE Act, boots WuXi
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — Madrigal wins first FDA nod for NASH